Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2013

View Archived Issues

Results show excellent reproducibility of in vivo [11C]-PBR-28 binding in MS

Recombinant BCG vaccine found safe and immunogenic in phase I study

Ferumoxytol-enhanced MRI shows potential for neuroimaging of patients with HAND

Identification of a novel DYRK1A inhibitor with the potential to prevent memory impairment in vivo

In vivo results suggest HIS-601 is a promising candidate for metabolic disorders

Merrimack Pharmaceuticals reports phase II MM-121 study results

Aragon Pharmaceuticals doses first patient in phase I study of ARN-810

X-Body Biosciences forms therapeutic antibody alliance

Gene silencing construct Tribetarna increases survival in lung cancer model

Promising interim results seen in phase III Lymphoseek trial in head and neck cancer

Astellas to collaborate with Ambrx on antibody-drug conjugates for cancer

Arena Pharmaceuticals begins phase I trial of APD-334

New antimalarial agents prepared at CSIR

Covis Pharma to acquire U.S. rights to several sanofi-aventis drugs

Otsuka Pharmaceutical patents novel prodrugs of brexpiprazole

Vertex and Bristol-Myers Squibb to conduct phase II studies of VX-135 and daclatasvir

Vital Therapies enrolls first patient in phase III trial of the ELAD system

A*STAR and Singapore Health Services synthesize new agents for bacterial infections

Clinical data on OTX-008 presented at AACR meeting

Blanchette Rockefeller Neurosciences Institute and Neurotrope BioScience form collaboration

VaxInnate receives NIH grant to develop recombinant tetravalent dengue vaccine

Novel itraconazole analogues designed by Johns Hopkins University

Roche presents new compounds for atherosclerosis and other disorders

Shire commences two phase II studies of product designed to facilitate hemodialysis

EMA extends review of Scenesse MAA for erythropoietic protoporphyria

FDA grants priority review for Bayer's riociguat NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...